Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bardoxolone Methyl

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Reata culls bardoxolone, ending decade of R&D on troubled kidney disease drug
    Reata culls bardoxolone, ending decade of R&D on troubled kidney disease drug

    11 May 2023

    // Kyle LaHucik ENDPTS

    https://endpts.com/reata-culls-bardoxolone-ending-decade-of-rd-on-troubled-kidney-disease-drug/

    Kyle LaHucik ENDPTS
    11 May 2023
    Share Share
    Reata, Kyowa Kirin ax bardoxolone, ending 13-year saga
    Reata, Kyowa Kirin ax bardoxolone, ending 13-year saga

    10 May 2023

    // Max Bayer FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/reata-kyowa-kirin-partnered-med-bardoxolone-faces-music-after-ph-3-flop-ending-13-year-saga

    Max Bayer FIERCE BIOTECH
    10 May 2023
    Share Share
    Reata Pharma to Report 2nd Quarter 2022 Financial Results
    Reata Pharma to Report 2nd Quarter 2022 Financial Results

    01 Aug 2022

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20220801005262/en

    BUSINESSWIRE
    01 Aug 2022
    Share Share
    Reata slips as FDA rejects kidney disease therapy
    Reata slips as FDA rejects kidney disease therapy

    26 Feb 2022

    // D. Lokuwithana SEEKING ALPHA

    https://seekingalpha.com/news/3806235-reta-stock-slips-as-fda-rejects-kidney-disease-drug

    D. Lokuwithana SEEKING ALPHA
    26 Feb 2022
    Share Share
    FDA slams Reata's kidney drug as ineffective ahead of adcomm meeting
    FDA slams Reata's kidney drug as ineffective ahead of adcomm meeting

    06 Dec 2021

    // Zachary Brennan ENDPTS

    https://endpts.com/fda-slams-reatas-kidney-drug-as-ineffective-ahead-of-adcomm-meeting-wednesday/

    Zachary Brennan ENDPTS
    06 Dec 2021
    Share Share
    Reata , Inc. Submits NDA for Company’s Lead Program: Bardoxolone
    Reata , Inc. Submits NDA for Company’s Lead Program: Bardoxolone

    01 Mar 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/fr/news-release/2021/03/01/2184047/0/en/Reata-Pharmaceuticals-Inc-Submits-NDA-for-Company-s-Lead-Program-Bardoxolone-in-Alport-Syndrome.html#:~:text=(Nasdaq%3A%20RETA)%20(%E2%80%9C,U.S.%20Food%20and%20Drug%20Administration

    GLOBENEWSWIRE
    01 Mar 2021
    Share Share